Table. 2.

Baseline predictors of evolution at end of follow-up (T2) (n = 59). Data are reported as % or median (percentiles 25th–75th)

	Amelioration of condition	No amelioration of condition	p value (univariate)	p value (multivariate)
Pain	3.0 (3.0–4.0)	4.0 (3.0–4.0)	p = 0.05*	p = 0.26
Fatigue	3.0 (3.0–4.0)	4.0 (3.0–4.0)	p = 0.15
Sleep problem	2.0 (1.0–4.0)	3.0 (2.0–4.0)	p = 0.06*	p = 0.18
Motricity	3.5 (2.0–4.0)	4.0 (3.0–4.0)	p = 0.38
Skin	2.0 (1.0–3.0)	2.0 (1.0–3.0)	p = 0.48
Dysautonomia	2.0 (2.0–3.0)	3.0 (2.0–3.0)	p = 0.32
Cardiac	0.0 (0.0–1.0)	0.0 (0.0–0.0)	p = 0.41
Bleeding	2.0 (1.3–3.0)	2.0 (1.0–3.0)	p = 0.11
GI	3.0 (2.0–3.0)	3.0 (1.0–3.0)	p = 0.38
Bladder	2.0 (0.3–3.0)	2.0 (1.0–4.0)	p = 0.79
TMJ	2.0 (0.0–3.0)	1.0 (0.0–3.0)	p = 0.73
ENT	2.0 (1.0–3.0)	1.0 (0.0–3.0)	p = 0.52
Visual	2.0 (1.0–3.0)	2.0 (0.0–3.0)	p = 0.71
Lung tract problem	2.0 (1.0–2.8)	2.0 (0.0–3.0)	p = 0.53
Sexual	0.5 (0.0–2.0)	1.0 (0.0–2.0)	p = 0.77
Cognitive	2.0 (0.0–2.0)	2.0 (1.0–4.0)	p = 0.22
Family history			p = 0.07*	p = 0.01**
No	22.22%	77.78%
Yes	58.70%	41.30%
Bone fragility			p = 0.77
No	53.49%	46.51%
Yes	60.00%	40.00%
DN4 +			p = 0.04*	p = 0.12
No	68.75%	31.25%
Yes	40.00%	60.00%
Suspected MCAS			p = 0.43
No	50.00%	50.00%
Yes	61.54%	38.46%

^*Statistically significant p < 0.10 (univariate). **Statistically significant p < 0.05 (multivariate). GI gastrointestinal. TMJ temporomandibular joint. ENT ear-nose-throat. MCAS mast cell activation syndrome. DN4 Douleur Neuropathique 4 (positive if > 4)